Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.43 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA7 | P43166 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168723 | 0.92 | PTPN1 (0.44) | CYP4F2CYP4A11PDCD1CD274CA12 | |
| SCHEMBL20179180 | 0.88 | CYP4F2 (0.46) | CYP4F2CYP4A11PDCD1CD274CA12 | |
| SCHEMBL20168700 | 0.86 | PTPRB (0.46) | CYP4F2CYP4A11CA12CA1CA2 | |
| SCHEMBL20168667 | 0.81 | ALDH1A1 (0.45) | PTPN1ALDH1A1SMN1; SMN2LMNAHTT | |
| SCHEMBL21570565 | 0.75 | PTPRB (0.55) | CYP4F2CYP4A11CA1CA2PTPN1 | |
| SCHEMBL20168303 | 0.73 | CYP4F2 (0.49) | CYP4F2CYP4A11PDCD1CD274CA12 | |
| SCHEMBL21570572 | 0.72 | LOXL2 (0.50) | CYP4F2CYP4A11RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL7855752 | 0.70 | CYP4F2 (0.67) | CYP4F2CYP4A11PDCD1CD274CA12 | |
| SCHEMBL13236273 | 0.70 | CYP4F2 (0.71) | CYP4F2CYP4A11PDCD1CD274CA12 | |
| SCHEMBL20179182 | 0.69 | CYP4F2 (0.47) | CYP4F2CYP4A11PDCD1CD274CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
| WO-2018094334-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | CYP4F2 1553/4885CYP4A11 3343/4885PDCD1 4395/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | CYP4F2 1219/4885CYP4A11 2515/4885PDCD1 4037/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | CYP4F2 1351/4885CYP4A11 2838/4885PDCD1 4436/4885 |
| US-11866394-B2 | Prodrugs of hydroxamate-based GCPII inhibitors | TPI1, HPGDS, GPI | CYP4F2 1219/4885CYP4A11 2515/4885PDCD1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.